Trial for Harm Reduction With Incentives & Vaping E-cigarettes (THRIVE)
Harm Reduction in Smokers With Obesity: Impact of Contingent Incentives and E-Cigarettes
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Cara M Murphy, Ph.D.
- Phone Number: 1 (401) 203-5339
- Email: THRIVE@brown.edu
Study Locations
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02912
- Brown University School of Public Health
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- BMI ≥ 25 kg/m2
- smoked ≥ 5 cigarettes/day during the past year
- 21 or older
- exhaled CO of > 6 ppm at Baseline
- willing to use ENDs for 6 weeks
- daily access to a Bluetooth-enabled smartphone/tablet
Exclusion Criteria:
- planning to set a smoking quit date in the next 30 days
- receiving smoking cessation treatment of any kind in the past 30 days
- currently using ENDS > 4 day per month
- hospitalized for mental illness in past 30 days
- heart-related event (e.g., heart attack, severe angina) in past 30 days
- resides with another person enrolled in the study
- pregnant, nursing, or planning to become pregnant in the next 6 months.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: ENDS and CI
Participants in this arm will receive information about the comparative risk of electronic nicotine delivery systems (ENDS) relative to smoking as well as 6 weeks' worth of provisions of ENDS and will receive 4 weeks of monetary incentives for complete abstinence from smoking (after a controlled ramp down of smoking).
|
Participants in active comparator groups that include ENDS will receive 6-weeks worth of ENDS supplies.
Other Names:
Participants in active comparator groups will receive incentives that vary based on participant abstinence from smoking, measured by a carbon monoxide breath sample.
Other Names:
|
|
Experimental: No ENDS and CI
Participants in this arm will receive information about the comparative risk of electronic nicotine delivery systems (ENDS) relative to smoking and will receive 4 weeks of monetary incentives for complete abstinence from smoking (after a controlled ramp down of smoking).
|
Participants in active comparator groups will receive incentives that vary based on participant abstinence from smoking, measured by a carbon monoxide breath sample.
Other Names:
Participants in active comparator groups labeled No ENDS will only receive information about the comparative risk of ENDS relative to combustible cigarettes.
|
|
Experimental: ENDS and NI
Participants in this arm will receive information about the comparative risk of electronic nicotine delivery systems (ENDS) relative to smoking as well as 6 weeks' worth of provisions of ENDS and will receive monetary incentives for providing breath samples only (non-contingent on smoking status).
|
Participants in active comparator groups that include ENDS will receive 6-weeks worth of ENDS supplies.
Other Names:
Participants in active comparator groups labeled NI will receive compensation for each breath sample provided throughout the study, with no variation.
Other Names:
|
|
Experimental: No ENDS and NI
Participants in this arm will receive information about the comparative risk of electronic nicotine devices (ENDs) relative to smoking and will receive monetary incentives for providing breath samples only (non-contingent on smoking status).
|
Participants in active comparator groups labeled No ENDS will only receive information about the comparative risk of ENDS relative to combustible cigarettes.
Participants in active comparator groups labeled NI will receive compensation for each breath sample provided throughout the study, with no variation.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Use of Cigarettes and ENDS
Time Frame: Assessed 4, 6, and 12 weeks follow-up
|
Daily use of cigarettes and ENDS will be determined using the Timeline Follow-Back (TLFB) in follow-up assessments post-treatment.
|
Assessed 4, 6, and 12 weeks follow-up
|
|
Within-Treatment Smoking Abstinence
Time Frame: Daily for 4 weeks
|
Number of days during the incentive period with CO verified abstinence from smoking
|
Daily for 4 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Motivation to change
Time Frame: Assessed 4, 6, and 12 weeks follow-up
|
Self-reported motivation, confidence, and importance of changing smoking and other tobacco & nicotine use behavior will be measured using motivation to change rulers
|
Assessed 4, 6, and 12 weeks follow-up
|
|
Carbon monoxide (CO)
Time Frame: Assessed 4, 6, and 12 weeks follow-up
|
Exhaled breath sample used to measure carbon monoxide
|
Assessed 4, 6, and 12 weeks follow-up
|
|
Weight
Time Frame: Assessed 4, 6, and 12 weeks follow-up
|
Measured body weight in pounds
|
Assessed 4, 6, and 12 weeks follow-up
|
|
Cigarette and E-Cigarette Dependence
Time Frame: Assessed 4, 6, and 12 weeks follow-up
|
Self-reported level of dependence on cigarettes and e-cigarettes will be assessed using the Population Assessment of Tobacco and Health (PATH) Study dependence questionnaire.
Items on this scale are scored from 1, "Not true of me at all", to 5, "Extremely true of me".
Higher scores represent higher levels of cigarette and e-cigarette dependence.
Minutes to first cigarettes daily will also be used to assess cigarette dependence with lower scores indicating greater cigarette dependence.
|
Assessed 4, 6, and 12 weeks follow-up
|
|
Comparing E-Cigarettes and Cigarettes Questionnaire
Time Frame: Assessed 4, 6, and 12 weeks follow-up
|
Attitudes towards e-cigarettes relative to cigarettes (i.e., general benefits, general effects, and health benefits), will be assessed using the Comparing E-Cigarette and Cigarettes (CEAC) Questionnaire.
Items on this questionnaire are scored from 1, "Strongly Disagree", to 5, "Strongly Agree" with higher score indicating greater agreement with benefits of e-cigarettes relative to cigarettes.
|
Assessed 4, 6, and 12 weeks follow-up
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Cara M Murphy, Ph.D., Brown University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Nutrition Disorders
- Overnutrition
- Body Weight
- Overweight
- Obesity
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Neurotransmitter Agents
- Cholinergic Agents
- Ganglionic Stimulants
- Nicotinic Agonists
- Cholinergic Agonists
- Nicotine
Other Study ID Numbers
Other Study ID Numbers
- 2022003359
- P20GM130414 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.